86761-31-1

Basic information

• Product Name: C₁₂H₁₄O₂
• Synonyms: C₁₂H₁₄O₂
• CAS NO: 86761-31-1
• Molecular Weight: 190.242
• Mol File: 86761-31-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: C₁₂H₁₄O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₂H₁₄O₂(86761-31-1)
• EPA Substance Registry System: C₁₂H₁₄O₂(86761-31-1)

Safety Data

• Hazardous Substances Data: 86761-31-1(Hazardous Substances Data)

Upstream product

• 31689-43-7 1-methyl-3-methylcyclohexa-2,5-dienecarboxylic acid 
• 292638-85-8 acrylic acid methyl ester 
• 608-28-6 2,6-dimethyliodobenzene 
• 5927-18-4 trimethyl phosphonoacetate 
• 1123-56-4 2,6-dimethylbenzaldehyde 

Downstream Products

• 1419258-92-6 C₂₅H₂₂ClFN₂O₂ 
• 1419258-65-3 1-(5-chloro-2-methylphenyl)-5-(2,6-dimethylphenyl)-3-(2-fluorophenyl)-4,5-dihydro-1H-pyrazole-4-carboxylic acid [2-(4-hydroxyphenyl)ethyl]amide 
• 1419258-90-4 C₂₆H₂₄ClFN₂O₂ 

Relevant articles and documents

Synthesis of Highly Substituted Arenes via Cyclohexadiene-Alkene C-H Cross Coupling and Aromatization

The development of a cross-coupling method for the regioselective β-alkenylation of 2,5-cyclohexadiene carboxylic acid derivatives to form ortho-alkenylarenes through in situ decarboxylation and aromatization is described. The carboxylic acid functionality is used as a traceless directing group for efficient and mild β-alkenylation. The modular sequence comprises a reductive Birch α-alkylation, ionic ?-alkylation followed by a Pd-catalyzed decarboxylative β-alkenylation with subsequent aromatization resulting in an overall three-fold ipso-para-ortho functionalization of readily accessed benzoic acid derivatives. Efficient synthesis of various alkyl-alkenylarenes under mild conditions in moderate to excellent yields is presented.

TARGETING GLI PROTEINS IN HUMAN CANCER BY SMALL MOLECULES

The present disclosure provides compositions, pharmaceutical preparations and methods for the diagnosis and treatment of cancers expressing a GLI polypeptide. The disclosed compositions and pharmaceutical preparations may comprise one or more pyrazolyl-containing compounds, or an analog or derivative thereof.